I have long planned to write my opinion on Cellceutix (OTCQB:CTIX), which I consider one of the most exciting oncology-focused biotech companies. Despite the usual risks of an early-stage biotech, I find their p53 activator compound Kevetrin one of the most interesting things to follow.
However, when Cellceutix acquired PolyMedix assets from bankruptcy in September 2013, I was not sure what to make out of it. A biotech company developing cancer drugs is buying an antibiotic company's assets? I must admit that my impression was not positive at first. I prefer when an early-stage biotech company stays focused on the key compounds. After some time, I analyzed the acquisition in more depth and started developing a sneaking...
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: